|Day Low/High||49.99 / 50.85|
|52 Wk Low/High||42.48 / 63.69|
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
We are currently in process of restoring my access that is blocking me from seeing or commenting on the Daily Diary. We hope to have the problem resolved soon. Our apologies while getting the issue resolved. The market is off to a solid start this F...
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
David Tepper's Appaloosa LP renews calls for changes at the top.
Experts offer their top stock ideas in oncology detection and treatment.
Management commentary from CAT is key on Monday.
Replacing fear with pragmatism, that is our goal.
These themes are working despite the turmoil in Washington and slowing global growth.
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
This is the kind of reversal that happens in a bull market.
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.
Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.
Once the safest stocks in the book, the big-cap drug companies are now toxic.